A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer (JUNIPER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02152631
Recruitment Status : Active, not recruiting
First Posted : June 2, 2014
Last Update Posted : October 19, 2017
Information provided by (Responsible Party):
Eli Lilly and Company

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Active, not recruiting
  Actual Primary Completion Date : September 2017
  Estimated Study Completion Date : November 2018

Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 August 23, 2018
(Canceled on August 23, 2018)
September 6, 2018
(Canceled on September 16, 2018)
September 20, 2018
(Canceled on October 1, 2018)
October 4, 2018
(Canceled on October 16, 2018)
October 17, 2018
November 14, 2018
2 November 16, 2018